How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any equality issues that need special consideration and are not covered in the medical technology consultation document?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Guidance assessment consultation document for GID-HTE10059 Artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures: Early Value Assessment

Closed for comments This consultation ended on at   Request commenting lead permission

4 Committee members and NICE project team

This topic was considered by NICE's diagnostics advisory committee, which is a standing advisory committee of NICE.

Committee members are asked to declare any interests in the technology to be evaluated. If it is considered there is a conflict of interest, the member is excluded from participating further in that evaluation.

The minutes of each committee meeting, which include the names of the members who attended and their declarations of interests, are posted on the NICE website.

Chair

Neil Hawkins
Vice chair, diagnostics advisory committee

NICE project team

Each evaluation is assigned to a team consisting of 1 or more health technology analysts (who act as technical lead(s) for the evaluation), a technical adviser, a project manager and an associate director.

Ivan Maslyankov
Technical lead

Judith Shore
Technical adviser

Deonee Stanislaus
Project manager

Rebecca Albrow
Associate director

ISBN: [to be added at publication]